Samsung Biologics has launched a 1.46 billion Swiss francs ($1.8 billion) all-cash public tender offer to acquire Switzerland's PolyPeptide Group, a specialist in peptide-based active pharmaceutical ingredients, with stockholders set to receive 44.31 Swiss francs per share. The transaction is anticipated to close by the end of 2026, marking the largest biopharmaceutical M&A deal in South Korea's history, according to Samsung Biologics [1].
The acquisition is strategically aimed at diversifying Samsung Biologics' portfolio, expanding beyond antibody drugs and antibody-drug conjugates into peptide therapeutics—a segment experiencing rapid growth due to rising demand for obesity treatments. Peptide therapeutics include GLP-1 drugs for obesity and diabetes, which mimic natural hormones to reduce appetite and regulate blood sugar [1].
PolyPeptide Group, headquartered in Baar, Switzerland and spun off from Ferring in 1996, has developed and produced over 1,000 therapeutic peptides. The deal will also enhance Samsung Biologics' global footprint by integrating PolyPeptide's network across Sweden, Belgium, France, the U.S., and India, covering R&D, development, and commercial manufacturing capabilities [1].
Peter Wilden, chairman of PolyPeptide, stated that the board considers Samsung Biologics' offer compelling, providing shareholders with an attractive cash price and immediate, certain value. Despite the strategic rationale, Samsung Biologics shares slipped 1.3% early Monday following the announcement [1].
CONCLUSION
Samsung Biologics' acquisition of PolyPeptide Group represents a significant move to capitalize on the fast-growing peptide therapeutics market, particularly for obesity and diabetes treatments. While the deal is expected to broaden Samsung Biologics' global reach and product offerings, the immediate market reaction was slightly negative, with shares declining 1.3% after the announcement.